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Abstract 
Background: There is a known interaction between pregnancy and rheumatic disease. Women 
with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are concerned about the 
potential impact of a pregnancy. Therefore, it is important to get more knowledge on how 
pregnancy affects these womens health related quality of life (HRQL). 
Purpose: To study changes in HRQL in Norwegian women with RA and JIA before, during 
and after pregnancy. 
Methods: A total 35 patients with RA and 27 patients with JIA were assessed up to six times 
(before pregnancy, once in each trimester, and at six weeks and six months postpartum) using 
the short form 36 (SF-36). In addition, these women were compared to a group of non-
pregnant reference women in the same age group, 66 women with RA and 33 women with 
JIA.  
Results: In the study group RA women had better HRQL than the JIA patients at baseline in 
the aspects of mental health, vitality and role physical. Independent of disease group the 
womens, experience of vitality was lower in 1st, 2nd and 3rd trimester compared to baseline. 
Six months postpartum, the RA women in the study group scored better in the aspects of 
social function, physical function, role physical and role emotional than the non-pregnant 
reference women with RA. 
Conclusion: HRQL was lower during pregnancy for both RA and JIA women. However, 
despite a wide range, the women seemed to reach the same level as pre-pregnancy at the time 
of six months postpartum.  
 
Relevance 
There are few studies done to assess health related quality of life (HRQL) in women with 
rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) related to pregnancy. There 
are a small number of women with RA and JIA giving birth each year in Norway, and 
planning a family is a big issue for these women. Getting more knowledge on how a 
pregnancy affects these women’s health related quality life from before pregnancy and to six 
months postpartum is valuable when consulting these women in the rheumatology unit.  
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Introduction  
 
This is a study about health related quality of life (HRQL) before, during and after pregnancy 
in Norwegian women with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). 
 
Disease characteristics 
RA and JIA are chronic, inflammatory autoimmune diseases characterised by destructive 
synovitis (Figure 1). Systematic involvement of joints of the hands and feet is common (1, 2), 
but all joints surrounded with synovia can be involved (3).  Inflammation in joints can be very 
painful, and ongoing disease activity can lead to major destruction and erosions in the joints if 
not treated (3). Pain and stiffness in these diseases occurs because of inflammation in the 
synovial cavity and tenosynovitis. The synovial lining is the soft tissue around the joint 
capsule. Tenosynovitis involves inflammation in the tendons and the tendon sheath. The 
inflammation often debuts in smaller joints, like the wrist and hands (3).  
 
Figur 1. Joint model. 
 
http://images.rheumatology.org/ (4) 
 
A flare in RA and JIA means an increase in disease activity. Living with RA or JIA can mean 
living with pain, stiffness, fatigue and reduced functioning (5). Both RA and JIA can lead to 
problems in the daily life, and especially when having small children (6). 
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Rheumatoid Arthritis (RA) 
RA usually debuts during 20-30 years of age, and is about 3 times more common in women 
than men (7). The prevalence of RA around the world is 0.5-1 % (8, 9). The incidence of RA 
in Norway is around 25 per 100000 (10). RA often occurs with a general feeling of sickness. 
The different symptoms can be fatigue, mild fever, pain and stiffness in the joints, and 
morning stiffness (3).  
 
In 2/3 of those diagnosed with RA, the disease develops slowly, whereas 1/3 have an acute 
debut (3). In some people, RA also affects organs such as heart, lungs, kidneys, eyes, the 
vascular system and the bone marrow (11). There are two serum tests that can be taken to set 
the RA diagnosis. The oldest one is the serum rheumatoid factor. In the latest years the anti-
CCP (anti-cyclic citrullinated peptide antibodies) is more used (12). 
  
RA is diagnosed with the 1987 American College of Rheumatology (ACR) criteria.  
 
The ACR criteria  
1. Morning stiffness for at least 6 weeks 
2. Arthritis for three or more joint areas for at least 6 weeks 
3. Arthritis of hand joints for at least 6 weeks 
4. Symmetric arthritis for at least 6 weeks 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes.  
RA is diagnosed if 4 of 7 items are present (13). 
 
Juvenile Idiopathic Arthritis (JIA) 
The most common of chronic rheumatic diseases that debuts in childhood is JIA. The debut of 
JIA is present in all years of childhood (8). Approximately 60 % of the children diagnosed 
with JIA are girls (8). About 50 % of the patients diagnosed with JIA in childhood, have an 
active disease in adulthood, and 50 % of them develop a polyarticular disease with five or 
more joints affected (14).  
 The prevalence of JIA is difficult to estimate, since large population studies are using 
different diagnostic criteria around the world, and there is a lack of a joint definition of an 
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active JIA. Due to this, the incidence worldwide is estimated to be 86-148/100000 children 
each year. The annual incidence of JIA in Norway is 14-23/100000 children, an estimate 
based on epidemiological studies (15). JIA is a disease that can affect smaller and larger 
joints, and other organs such as eyes. As a consequence, this can lead to reduced function, 
pain and stiffness. JIA can also affect growth in childhood (16). 
 
JIA is diagnosed differently over the years with The American College of Rheumatology 
(ACR) have criteria’s from 1977, the  European League against Rheumatism (EULAR) 
criteria’s from 1977, and the International League of Associations of Rheumatologists (ILAR) 
criteria’s from 1997 (15).  
 
The ACR criteria`s for juvenile rheumatoid arthritis (JRA) is used for patients included in this 
study. The ACR criteria are set at debut < 16 years of age, duration of arthritis at ≥ 6 weeks, 
and include systematic polyarticular disease and pauciarticular disease. Excluded subgroups 
are juvenile ankylosing spondylitis, juvenile psoriatic arthritis and arthritis associated with 
inflammatory bowel disease (15). Since 1997 the name JIA has been used, also on the patients 
diagnosed before 1997.  
 
Disease modifying anti-rheumatic drugs (DMARDs) 
Many of the patients with RA and JIA are in need of drugs to keep their disease in remission. 
DMARDs are frequently used in treating arthritis in Norway. There are two different types of 
DMARDs, synthetic DMARDs and biological DMARDs. Not all drugs are consistent with 
conception, pregnancy and lactation. Because of this it is important to adjust the drugs in a 
period of planning a pregnancy (17).  
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Fertility and pregnancy 
RA and JIA can influence fertility due to different mechanisms like physical, psychological, 
hormonal and immunological as well as medical treatments (2, 18). According to two 
Norwegian studies of fertility and parity, women with arthritis have a higher proportion of 
nullparous compared to the normal population (19). In addition, women with RA have a lower 
parity than women with JIA (20).  
 
Pregnancy is in general a big change both organic and hormonally (1). There is a well-known 
interaction between pregnancy and inflammatory rheumatic disease (2, 21, 22).   Pregnancy 
affects the rheumatic disease, and the rheumatic disease affects the pregnancy (23). According 
to Forger and Østensen (2005) the negative symptoms during pregnancy are often dominating 
in healthy women. In woman with chronic inflammatory diseases a focus on the positive sides 
of becoming a mother is more often seen (1).  
 
Most of the women with RA experience a decreased disease activity during pregnancy (24, 
25). Most frequently a decreased disease activity is seen during pregnancy in women that are 
rheumatoid factor negative or anti-CCP negative (26). Around 40 % of all women with RA 
experience a flare postpartum within 3-6 months after delivery (22).  
 
For women with JIA that have been in remission during the early adulthood, a flare related to 
pregnancy is not expected (16). About 50 % of the women with JIA with active disease in 
adulthood can expect the disease activity to be the same, or better during pregnancy (16, 27). 
Around 50 % of women with JIA can expect a flare within 3-6 months postpartum (16, 24).  
 
Health Related Quality of Life (HRQL) 
The term quality of life (QOL) has over the years become an important part of medical 
research (28, 29). There are a lot of different definitions of QOL that reflects the origin they 
were developed for (28, 29). Researchers have agreed that the term QOL is subjective and 
involves different aspects of life (28).  
In line with this agreement, the World Health Organisation (WHO) has defined quality of life 
as: “individual’s perception of their position in life in the context of the culture and the value 
systems in which they live, and in relation to their goals, expectations, standards and 
concerns” (30). 
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QOL is a broader concept than HRQL. Distinguished from QOL, HRQL include those aspects 
of life that are most related to health status, instead of living standards and environment (31).  
 
Ware et al (1995) have defined eight HRQL aspects of importance i.e. physical functioning, 
role physical, bodily pain, general health, vitality, social functioning, role emotional and 
mental health (31).  
 
Living with a chronic rheumatic disease leads to challenges on different levels, and may have 
a major impact on physical and mental health (32). Measurements of disease activity and 
disease related function does not always cover what is most important in the everyday life in 
people with RA and JIA. HRQL is an important aspect of the women living with chronic 
rheumatic disease (1). Previous studies have shown that RA and JIA have a negative effect on 
HRQL in women (33, 34). A study of young females with JIA have shown that they have 
lower HRQL, and also achieved less milestones in life compared to healthy women (35). 
During pregnancy, the hormonal and organ specific changes may alter not only the physical 
functioning, but also mental wellbeing (1, 21).  
 
Only one small study has prospectively evaluated the impact of pregnancy on HRQL in 
pregnant women with a rheumatic disease with the SF-36 (1). This study had a small number 
of subjects, only 10 with each rheumatic disease, RA and ankylosing spondylitis. Even so, the 
study concluded with that pregnancy had no impact on mental and emotional health. No 
studies have assessed HRQL before, during and after pregnancy in Norwegian women with 
RA and JIA.  
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Aim of the study 
The aim of this study is to assess women with RA and JIA before, during and after pregnancy 
in order to explore if the pregnancy influence HRQL.  
 
The specific aims of this study are to: 
- Compare the RA and JIA patients pre-pregnancy to non-pregnant reference women 
with RA and JIA in the same age at baseline and six months postpartum 
- Explore the differences in HRQL between the RA and JIA patients in pregnancy, 
compared to non-pregnant reference women with RA and JIA in the same age  
- Explore the longitudinal changes in HRQL in woman with RA and JIA from before 
pregnancy, during pregnancy and up to six months postpartum 
- Explore the longitudinal changes in disease activity and function score, scored by 
DAS-28 and MHAQ in women with RA and JIA from before pregnancy, during 
pregnancy and to six months postpartum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
Methods 
 
Design 
This is a longitudinally observational study. Women were included if they were diagnosed 
with RA or JIA, assessed before, during and after pregnancy and enrolled in the RevNatus 
registry. A reference group of non-pregnant women with RA and JIA in the same age group 
was included from the NOR-DMARD (The Norwegian Disease Modifying Anti Rheumatic 
Drug Register). 
 
Subjects 
 
RevNatus sample 
Women in fertile age ≥18 years diagnosed with RA or JIA after the ACR criteria were 
included (36, 37). RevNatus is administrated at the National Service for Pregnancy and 
Rheumatic Diseases in Trondheim, Norway (Appendix 1).  There are 12 rheumatology units 
in Norway that are including patients in RevNatus. The number of rheumatology units 
involved has increased since the register was established at St. Olavs Hospital in 2006. 
Registrations are done pre-pregnancy, in the 1st trimester (0-12 weeks), 2nd trimester (13-27 
weeks), 3rd trimester (28-40 weeks), six weeks after delivery, six months and 12 months 
postpartum. Patients are also included during pregnancy. All women included in this study 
from RevNatus had live births. The data from RevNatus available for this study are collected 
from 2006-2012. For the present study, data for visits up to six months postpartum were 
available. This group will be referred to as the study group in this thesis. 
 
NOR-DMARD reference sample   
A reference group of non-pregnant women, in the same age group as the RevNatus sample, 
with RA and JIA in the NOR-DMARD registry was used for comparison. In this study, the 
patients from the Trondheim population of NOR-DMARD were available. All reference 
patients from the NOR-DMARD registry are expected to have their disease activity in control 
after six months of treatment with the same regime. Each person in the NOR-DMARD 
registry is evaluated three months after starting a new drug regime, and drug treatment is 
changed if disease activity is not changed to the better at that point of time. The data from 
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NOR-DMARD available for this study was collected from 2000-2010. This group of patients 
will be referred to as non-pregnant reference women in this thesis.  
Measures 
Both the pregnant and the non-pregnant reference women with RA and JIA have been 
assessed with SF-36 for HRQL, disease activity with disease activity score 28 (DAS-28-
CRP(3)), and disease related function with Modified Health Assessment Questionnaire 
(MHAQ).     
 
The Short Form 36 (SF-36) 
The Short Form SF-36 (version 1.2) is a generic self-reported instrument used in health care 
and in clinical trials to measure HRQL and, normally, it takes approximately 5 minutes to 
complete (38).  
 
The 36 short form questions are grouped into eight multi-item subscales covering eight HRQL 
aspects, i.e. physical functioning including 10 items, role physical with four items, role 
emotional with three items, bodily pain with two items, social functioning with two items, 
mental health with five items, vitality with four items and general health with five items (See 
table X for more information) (31, 38).  
 
Each item has two to six response categories and each aspect is calculated, using the SF-36 
manual. The score are ranging from 0-100, where 0 is the worst possible situation, and 100 is 
the best possible situation (38) (Table 1).   
 
The SF-36 has been translated into Norwegian and been validated in people living with RA 
(39, 40) and has been used in studies of pregnant women with RA (1, 41). 
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Table 1. Aspects of SF-36 (31). 
Aspects Lowest possible Score Highest possible Score 
Physical Functioning PF Very limited in performing all physical 
activities, including bathing or dressing 
Performs all types of physical activities 
including the most vigorous without 
limitations due to health 
Role- Physical RF Problems with work or other daily activities 
as a result of physical health 
No problems with work or other daily 
activities 
Bodily pain BP Very severe and extremely limiting pain No pain or limitations due to pain 
General Health GH Evaluates personal health as poor and 
believes it is likely to get worse 
Evaluates personal health as excellent 
Vitality VT Feels tires and worn out all of the time Feels full of pep and energy all of the time 
Social Functioning  Extreme and frequent interference with 
normal social activities due to physical and 
emotional problems 
Performs normal social activities without 
interference due to physical or emotional 
problems 
Role-Emotional RE Problems with work or other daily activities 
as a result of emotional problems 
No problems with work or other daily 
activities 
Mental Health MH Feelings of nervousness and depression all 
of the time 
Feels peaceful, happy, and calm all of the 
time 
  
 
Disease activity score 28 (DAS-28) 
DAS-28(Appendix 3)  is a validated measurement for disease activity in patients with RA 
(22), and is widely used on JIA. It contains of joint count, 28 joints are assessed for swollen 
and tenderness. In addition, a c-reactive protein value (CRP) or sedimention rate (ESR) value 
is included in making a score. The physician’s or patient’s measurement of general health on 
a visual analogue scale (VAS) can be included in the DAS-28. The DAS-28 comes in four 
different versions depending on the number of measurements, and if CRP or ESR is chosen. 
The DAS-28(4), DAS-28(3), DAS-28-CRP(4), DAS-28-CRP(3). 
 
Because the pregnancy itself can influence the scoring with a natural elevation of ESR during 
pregnancy, the DAS-28-CRP(3) with three different measurements and CRP is considered the 
most reliable (42). The score is ranging from 0 to 9.1, whereas < 2.6 is considered as 
remission, < 3.2 is low disease activity, and > 5.1 is considered as high disease activity (43). 
DAS-28-CRP(3) has previously been used for rheumatic patients during pregnancy (22, 42). 
 
 
 
 
Modified health assessment questionnaire (MHAQ)  
16 
 
MHAQ measures disease related function in patients with arthritis (44) (Appendix 4). MHAQ 
has previously been used to measure disease related function in patients with RA and JIA 
(40), and has been used in rheumatic pregnant women (22). MHAQ has been translated and 
validated into Norwegian (39). MHAQ includes eight questions on disease related function 
with patients ticking a 4-point Likert scale from 0 to 3, where 0 means no problem, 3 means 
unable to perform (44, 45). The eight scores are summarized and divided with eight to get the 
total MHAQ score wich is ranging from 0 to 3 (45).  
 
Additional measures 
Baseline characteristics on disease duration, age and work status from both the study group 
and the non-pregnant reference women with RA and JIA were available. Age and disease 
duration in the study group were registered in RevNatus at the first visit when pregnant, and 
for the non-pregnant reference women at time of inclusion in NOR-DMARD. Disease 
duration was set at years and months. Work status was defined as working or not working. 
Working was defined as more than five hours a week and students were categorized as 
working.  The number of DMARDs was registered at each visit.  
 
Procedures and ethics 
Women included in RevNatus and NOR-DMARD were invited with written and oral 
information. All women included in this study have given their written confirmed content 
(Appendix 1 and Appendix 2) to be registered in RevNatus or NOR-DMARD, and were 
informed that the data would be used in research. The study was approved by the Regional 
Committee for Medical and Health Research (REK) (2012/447/REKmidt).  
 
Statistical Methods 
To analyse this dataset we used the Statistical Package for Social Sciences (SPSS) version 18. 
The data from the study group was manually put into the SPSS. All data was controlled twice. 
The data from the non-pregnant reference women was scanned into the SPSS file and was 
delivered in a data file to this study. All the results were controlled by two persons after doing 
the analysis twice.  
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The descriptive statistics was done with Chi-square test or Fisher exact test (depending on the 
sample size and distribution under study) for categorical data. Continuous data are presented 
with mean scores and 95 % confidence intervals (CI).  
 
When comparing the scores of eight aspects of SF-36, the DAS-28-CRP(3) and MHAQ in the 
RA and JIA women in the study group to the non-pregnant reference women with RA and 
JIA, the Mann-Whitney U test was used. Using the conservative non-parametric Mann-
Whitney U test was chosen since the numbers of observations were relatively few, the 
normality of the distribution could be questioned and this method was regarded as equally 
good as the two sample t-test. The test looks for differences in independent groups of samples 
in order to find if one of the groups have larger values than the other (46). 
 
Changes in the eight aspects of HRQL were measured by the SF-36, DAS-28 and MHAQ 
were explored in the study group from pre-pregnancy and through six months postpartum, 
using the generalized mixed effect model for incomplete dataset in order to explore change by 
time point and rheumatic disease. This model is normally used for normal distributed data, 
and there is no good alternative for this type of tests for non-normal distributed data. When 
looking at the distribution of the data, there were no severe deviations from normal 
distribution, and using this test was considered as relevant. The reference level in the 
generalized mixed effect model was JIA women and the pre-pregnancy scores.   
 
In addition to the generalized mixed effect model analysis of incomplete dataset of change in 
HRQL, DAS-28 and MHAQ in the study group, change in each of the RA and JIA women in 
the study group from pre-pregnancy throughout the pregnancy and up to six months 
postpartum was studied using the Wilcoxon test for related samples.  
 
In this study the significance level was set to <0.05. All findings were looked at not only for 
p-value, but also for the relevance in this patient group.  
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Results 
 
The flowchart (Figure 2) describes the slightly increasing number of RA women in the study 
group from before, during and after pregnancy, and the somewhat inconsistent number of JIA 
women in the study group throughout the pregnancy and postpartum. All available patients in 
the study group were included in this study, but between 2nd and 3rd trimester, and between six 
weeks and six months postpartum some JIA women were lost to follow-up. All of the women 
in the study group with both RA and JIA with a pre-pregnancy visit were also assessed at six 
months postpartum.  
 
Figure 2. Flowchart of the study group.  
Pre-pregnancy 
 RA     N = 19 JIA     N = 9  
▼ 
1st trimester 
→ 7 RA     N = 26 JIA     N = 13 ← 4 
▼ 
2nd trimester 
→ 3 RA     N = 29 JIA     N = 27 ←14 
▼ 
3rd trimester 
→ 3 RA     N = 32 JIA     N = 22 → 5 
▼ 
6 weeks postpartum 
→ 3 RA     N = 35 JIA     N = 25 ←3 
▼ 
6 months postpartum 
 RA     N = 35 JIA     N = 20 → 5 
 
Women meeting the inclusion criteria for the non-pregnant reference women were 66 non-
pregnant women with RA and 33 non-pregnant women with JIA, all from the 3rd visit in the 
NOR-DMARD registry.  
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Patient characteristics 
The RA and JIA women in the study group were comparable to the non-pregnant RA and JIA 
reference women in baseline characteristics, except that the study group used less DMARDs 
and the JIA women in the study group had lower score on DAS-28-CRP(3) compared to the 
non-pregnant reference women with JIA(Table 2). The study group women used less 
DMARDs compared to the non-pregnant reference women six months postpartum.  
 
Table 2. Patient characteristics for the study group and non-pregnant reference women 
with Rheumatoid Arthritis (RA) and Juvenile Idiopatic Arthritis (JIA). 
  Study groupa 
 
Non-pregnant 
reference women 
  RA JIA RA JIA 
Age b Mean  
(95% CI) 
31.4  
(29.9-32.4) 
27.8 
(25.9-29.7) 
32.7 
(31.7-33.7) 
27.6 
(25.8-29.3) 
Disease duration Mean  
(95% CI) 
6.4 
(4.9-7.9) 
20.5 
(18.0-23.0) 
6.7 
(5.6-7.8) 
15.4 
(13.2-17.7) 
DAS-28-CRP(3)  
    Baseline 
 
    6 months p.p 
 
Mean  
(95% CI) 
Mean  
(95% CI) 
 
3.0 
(2.4-3.5) 
2.5 
(2.2-2.8) 
 
2.1c 
(1.7-2.6) 
3.0 
(2.5-3.6) 
 
3.1 
(2.8-3.4) 
 
3.2 
(2.7-3.7) 
MHAQ 
    Baseline 
 
    6 months p.p 
 
Mean  
(95% CI) 
Mean  
(95% CI) 
 
0.28 
(0.10-0.45) 
0.24 
(0.11-0.37) 
 
0.06 
(0.007-0.12) 
0.47 
(0.25-0.70) 
 
0.39 
(0.28-0.49) 
 
0.48 
(0.29-0.67) 
DMARDs 
    Baseline 
 
    6 months p.p. 
 
Mean  
(95% CI) 
Mean  
(95% CI) 
 
0.44d 
(0.15-0.73) 
0.91f 
(0.65-1.17) 
 
0.53e 
(0.20-0.86) 
0.57g 
(0.31-0.82) 
 
1.48 
(1.34-1.62) 
 
1.45 
(1.24-1.67) 
 
Work statush 
In work  
     Baseline     
 
 
(N) % 
 
 
(13) 70 % 
 
 
(5) 71.4 % 
 
 
(31) 60.4 % 
 
 
(11) 46.2 % 
a All statistical comparisons between the RA and JIA women in the study group and the non-pregnant reference women with RA and JIA 
were performed with the Mann-Whitney U test 
b Age is taken from the first RevNatus visit that the patient is pregnant, and the first NOR-DMARD visit.  
c The study group of JIA women scored lower in DAS-28-CRP(3) at baseline compared to the non-pregnant reference women, p=0.03  
d The study group of RA women used less DMARDs at baseline compared to the non-pregnant reference women, p<0.01  
e The study group of JIA women used less DMARDs at baseline compared to the non-pregnant reference women , p<0.01  
f The study group of RA women used less DMARDs at 6 months postpartum compared to the non-pregnant reference women, p<0.01   
g The study group of JIA women used less DMARDs at 6 months postpartum compared to the non-pregnant reference women, p<0.01  
h There are some missing data in the dataset for work status. The percentage in work is calculated from them with registered with work status, 
and N is the number in each group working.  
Eventually differences in work status between the study group and non-pregnant reference women with RA and JIA were tested with Fisher 
exact test 
p.p = postpartum 
C.I. = confidence interval 
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Health Related Quality of Life 
 
HRQL in the study group compared to the non-pregnant reference women 
The scores of HRQL from SF-36 for the study group are presented with mean and 95% CI in 
Table 3 and 4.  
At baseline (pre-pregnancy), the RA women in the study group had better physical function 
than the non-pregnant reference women with RA (p=0.03) and the JIA women in the study 
group had higher vitality (p=0.04) and general health (p=0.02) score than the non-pregnant 
reference women (p=0.02), but otherwise they did not differ significantly. The women with 
JIA in the study group did not differ from the non-pregnant reference women at any other 
points.  
 
The RA women in the study group had at 1st trimester a better score in the aspect of role 
emotional than the non-pregnant reference women (p=0.05). In the 3rd trimester the RA 
women in the study group scored lower in the aspect of role physical than the non-pregnant 
reference women (p<0.01). 
 
At six months postpartum the RA women in the study group scored better in the aspects of 
social function, physical function, role physical and role emotional than the non-pregnant 
reference women (p<0.05).  
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Table 3. Mean scores and 95 % confidence interval (CI) of each SF-36 dimension in the study group women and non-pregnant reference 
women with Rheumatoid Arthritis (RA). 
  Study group 
RAa 
Non-pregnant reference 
women 
RA 
  Pre-pregnancy 1st  trimester 2nd  trimester 3rd  trimester 
 
6 weeks 
postpartum 
6 months 
postpartum 
3rd  visit 
 
N 
 
 19 26 29 32 35 35 63 
Mental Health 
 
Mean 
95% CI 
81  
(74-87) 
84 
(80-88) 
80  
(75-86) 
82  
(78-86) 
83  
(79-87) 
86 
(83-89) 
79  
(75-83) 
Vitality  
 
Mean 
95% CI 
52 
(74-87) 
41 
(32-50) 
42 
(33-50) 
44 
(36-53) 
51 
(44-58) 
57 
(50-64) 
47 
(42-53) 
Social Function 
 
Mean 
95% CI 
84 
(75-93) 
75 
(66-84) 
76 
(68-85) 
76 
(68-83) 
75 
(66-84) 
86b 
(78-94) 
75 
(69-81) 
Role Emotional  
 
Mean 
95% CI 
84 
(70-99) 
95c 
(89-101) 
80 
(66-93) 
84 
(73-94) 
88 
(78-98) 
92d 
(84-101) 
81 
(74-89) 
Bodily Pain  
 
Mean 
95% CI 
62 
(51-72) 
61 
(51-72) 
54 
(43-65) 
59 
(49-70) 
60 
(51-69) 
62 
(53-71) 
54 
(47-60) 
General Health  
 
Mean 
95% CI 
60 
(51-69) 
60 
(51-68) 
57 
(49-66) 
59 
(52-66) 
61 
(53-68) 
67 
(60-74) 
62 
(57-68) 
Physical Function  
 
Mean 
95% CI 
80e 
(68-91) 
73 
(63-83) 
69 
(59-79) 
60 
(51-70) 
71 
(61-82) 
78f 
(69-87) 
67 
(60-73) 
Role Physical  
 
Mean 
95% CI 
62 
(44-80) 
51 
(34-67) 
41 
(25-58) 
23g 
(10-35) 
53 
(36-69) 
69h 
(54-84) 
51 
(41-62) 
The score is ranging from 0-100 where 0 is worst possible health is, 100 is best possible health. 
a All statistical comparisons between the RA and JIA women in the study group and the non-pregnant reference women with RA and JIA were performed with the Mann-Whitney U test 
b The study group of RA women scored better in the aspect of social function at 6 months postpartum compared to the non-pregnant reference women, p=0.027  
c The study group of RA women scored better in the aspect of role emotional at 1st trimester compared to the non-pregnant reference women, p=0.045 
d The study group of RA women scored better in the aspect of role emotional at 6 months postpartum compared to the non-pregnant reference women, p=0.04  
e The study group of RA women scored better in the aspect of physical function at pre-pregnancy compared to the non-pregnant reference women, p=0.03  
f The study group of RA women scored better in the aspect of physical function at 6 months postpartum compared to the non-pregnant reference women, p=0.015  
g The study group of RA women scored lower in the aspect of role physical at 3rd trimester compared to the non-pregnant reference women, p=0.001  
h The study group of RA women scored better in the aspect of role physical at 6 months postpartum compared to the non-pregnant reference women, p=0.04 
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Table 4. Mean scores and 95 % confidence interval (CI) of each SF-36 dimension in the study group women and non-pregnant reference 
women with Juvenile Idiopathic Arthritis (JIA). 
  Study group 
JIAa 
Non-pregnant 
reference women 
JIA 
  Prepregnancy 1st trimester 
 
2nd  trimester 
 
3rd  trimester 
 
6 weeks 
postpartum 
6 months 
postpartum 
3rd  visit 
 
N 
 
 9 13 27 22 25 20 30 
Mental Health 
 
Mean 
95% CI 
80 
(70-90) 
82 
(73-90) 
74 
(66-82) 
79 
(73-85) 
73 
(66-81) 
76 
(71-82) 
76  
(69-90) 
Vitality  
 
Mean 
95% CI 
57b 
(42-72) 
40 
(25-55) 
39 
(29-48) 
39 
(30-49) 
36 
(29-43) 
40 
(30-50) 
41 
(32-50) 
Social Function 
 
Mean 
95% CI 
89 
(75-103) 
79 
(67-91) 
74 
(64-83) 
73 
(63-82) 
65 
(55-75) 
66 
(53-79) 
73 
(63-83) 
Role Emotional  
 
Mean 
95% CI 
100 
 
93 
(85-101) 
68 
(51-85) 
80 
(66-95) 
60 
(43-77) 
60 
(40-80) 
72 
(57-88) 
Bodily Pain  
 
Mean 
95% CI 
66 
(46-86) 
54 
(43-65) 
54 
(44-64) 
51 
(41-62) 
45 
(51-69) 
41 
(31-51) 
52 
(41-63) 
General Health  
 
Mean 
95% CI 
75c 
(57-92) 
63 
(47-80) 
58 
(48-67) 
61 
(52-69) 
52 
(42-61) 
45 
(35-56) 
54 
(45-64) 
Physical Function  
 
Mean 
95% CI 
81 
(68-93) 
70 
(57-83) 
66 
(56-77) 
59 
(51-67) 
63 
(53-74) 
64 
(53-76) 
65 
(55-75) 
Role Physical  
 
Mean 
95% CI 
64 
(32-96) 
54 
(31-77) 
43 
(26-59) 
35 
(18-52) 
30 
(15-45) 
35 
(16-54) 
47  
(30-63) 
The score is ranging from 0-100 where 0 is worst possible health is, 100 is best possible health. 
a All statistical comparisons between the RA and JIA women in the study group and the non-pregnant reference women with RA and JIA were performed with the Mann-Whitney U test 
b The study group of JIA women scored better in the aspect of vitality at pre-pregnancy compared to the non-pregnant reference women, p=0.043  
c The study group of JIA women scored better in the aspect of general health pre-pregnancy compared to the non-pregnant reference women, p=0.045  
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HRQL in the RA and JIA study group women  
Using the generalized mixed effect model analysis for incomplete dataset, we found that RA 
women had better HRQL than the JIA women in some aspects at baseline, i.e. the mental 
health, vitality and role physical aspects of SF-36 (Table 5). The RA women seems to have 
somewhat higher scores on social function than the JIA women, although not significantly 
higher (p=0.07). Independent of the disease group the women belonged to (RA or JIA), their 
experience of vitality was lower at 1st trimester, 2nd trimester and 3rd trimester, compared to 
pre-pregnancy. Furthermore, independently of disease group they experienced more bodily 
pain (lower score) six weeks postpartum, and poorer general health and lower physical 
functioning at the 3rd trimester, compared to pre-pregnancy. In addition, the general health, 
tended to be lower in the 2nd trimester and six weeks postpartum (p=0.07 and p=0.06, 
respectively). Lastly, independent of the disease group the pregnant women belonged to, they 
experienced a lower role physical in the 1st trimester. The Wilcoxon test for two related 
samples performed in the RA and JIA women in the study group separately could partly 
confirm the generalized mixed effect model results, i.e. women with RA had lower physical 
function and role physical in 3rd trimester, and women with JIA had lower for physical health 
in 3rd trimester and lower general health six months postpartum.  
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Table 5. Generalized mixed effect model presented with ß-coefficient and 95 % confidence interval (CI) of eight aspects of HRQL by  
SF-36 in the study group women. 
  RA 1st trimester 2nd trimester 3rd trimester 6 weeks postpartum 6 months postpartum 
Mental Health ß-coeffisient 
95% CI 
7.03a 
(2.06 - 11.99) 
4.00 
(-1.52 - 9.52) 
-0.59 
(-5.77 - 4.60) 
2.02 
(-3.20 - 7.43) 
0.66 
(-4.53 - 5.85) 
2.78 
(-2.42 - 7.99) 
Vitality 
 
ß-coeffisient 
95% CI 
9.08b 
(0.69 - 17.46) 
-9.44c 
(-17.38 - -1.50) 
-9.60c 
(-17.06 - -2.14) 
-8.00c 
(-15.52 - -0.47) 
-5.73 
(-13.20 - 1.75) 
-1.84 
(-9.33 - 5.66) 
Social Function ß-coeffisient 
95% CI 
9.05 
(-0.97 - 19.08) 
0.05 
(-9.22 - 9.32) 
-3.41 
(-12.12 - 5.30) 
-2.54 
(-11.33 - 6.25) 
-5.27 
(-13.98 - 3.44) 
-3.93 
(-12.70 - 4.84) 
Role Emotional ß-coeffisient 
95% CI 
5.17 
(-3.90 – 14.25) 
-0.72 
(-8.15 - 6.73) 
-2.69 
(-9.68 - 4.30) 
-0.78 
(-7.84 - 6.27) 
-4.77 
(-11.78 - 2.25) 
-2.34 
(-9.37 -  4.68) 
Bodily Pain 
 
ß-coeffisient 
95% CI 
6.42 
(-2.79 - 15.63) 
-4.73 
(-13.54 - 4.07) 
-5.01 
(-13.28 - 3.26) 
-5.99 
(-14.33 - 2.36) 
-9.97 d 
(-18.22 - -1.72) 
-2.81 
(-11.12 - 5.50) 
General Health 
 
ß-coeffisient 
95% CI 
5.09 
(-5.58 - 15.77) 
-1.64 
(-9.67 - 6.40) 
-6.90 
(-14.45 - 0.65) 
-15.58e 
(-23.20 - -7.95) 
-7.12 
(-14.66 - 0.43) 
-1.80 
(-9.39 - 5.79) 
Physical Function 
 
ß-coeffisient 
95% CI 
8.25 
(-6.47 - 22.98) 
-3.85 
(-20.86 - 13.16) 
-13.94 
(-29.93 - 2.04) 
-29.96f 
(-45.99 - -13.93) 
-13.16 
(-29.09 - 2.76) 
0.61 
(-15.43 - 16.64) 
Role Physical 
 
ß-coeffisient 
95% CI 
16.48g 
(4.66 - 28.30) 
13.01h 
(-0.02 - 26.04) 
-4.32 
(-16.64 - 7.99) 
1.91 
(-10.54 - 14.35) 
-3.36 
(-15.64 - 8.92) 
-1.48 
(-13.88 -10.91) 
The reference level in the generalized mixed effect model was JIA women, and the pre-pregnancy scores.   
a The mental health aspect of SF-36 was  significantly better in women with RA at baseline compared to women with JIA, p=0.005  
b In the aspect of vitality the women with RA in the study group is significantly better than the JIA women, p=0.031 
c The vitality aspect of SF-36 was reduced at 1st, 2nd and 3rd trimester compared to prior pregnancy, p=0.02, 0.012 and 0.037 
d The women in the study group had lower scores in the aspect of bodily pain at six weeks postpartum, p=0.018 
e The women in the study group had lower scores in the aspect of general health at 3rd trimester, p<0.01 
f The women in the study group had lower scores in the aspect of physical health at 3rd trimester, p<0.01 
g In the aspect of role physical the women with RA in the study group is significantly better than the JIA women, p=0.006 
h The women in the study group had better scores in the aspect of physical health at 1st  trimester, p=0.0
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Disease activity during and after pregnancy 
In the generalized mixed effect model for disease activity (DAS-28-CRP(3)) (See table 6) 
there was no difference in disease activity between the women with RA and JIA in the study 
group at baseline, and the disease activity during and after pregnancy did not change 
compared to pre-pregnancy (Table 6). The nonparametric test for dependent samples 
(Wilcoxon test) was performed separately for the study group women with participating at 
both time points confirms these results (p>0.05). 
 
Changes in disease related function during and after pregnancy 
In the generalized mixed effect model for disease related function (MHAQ) there was no 
difference between the women in the study group with RA and JIA at baseline (Table 6). 
Independent of disease in the study group the disease related function was poorer (higher 
score) at 3rd trimester and at six weeks postpartum. The separate nonparametric analysis for 
dependent samples (Wilcoxon test) of RA and JIA women in the study group mainly 
confirmed the results from the generalized linear mixed model finding that the MHAQ score 
in the 3rd trimester was higher compared to pre-pregnancy, but the result concerning six weeks 
postpartum found in generalized linear mixed model was not confirmed.  
 
 
Table 6. Generalized mixed effect model presented with ß-coefficient and 95 % 
confidence interval (CI) of DAS-28-CRP(3) and MHAQ in the study group women. 
  RA 1st trimester 2nd trimester 3rd trimester 6 weeks 
postpartum 
6 months 
postpartum 
DAS-28- 
CRP(3) 
ß-coeffisient 
95% CI 
0.03 
(-0.88 - 0.94) 
0.23 
(-1.33 - 1.78) 
<-0.01 
(-1.48 - 1.47) 
-0.21 
(-1.67 - 1.26) 
0.35 
(-1.08 - 1.79) 
0.68 
(0.76 - 2.12) 
MHAQ 
 
ß-coeffisient 
95% CI 
-0.08 
(-0.25 - 0.10) 
-0.02 
(-0.18 - 0.14) 
0.09 
(-0.05 - 0.24) 
0.24a 
(0.10 - 0.39) 
0.16a 
(0.01 - 0.30) 
0.05 
(-0.10 - 0.20) 
The reference level in the generalized mixed effect model was JIA women, and the pre-pregnancy scores.   
a The women in the study group had higher scores in MHAQ at 3rd trimester and six weeks postpartum compared to prior pregnancy   
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Discussion  
 
Six months postpartum the RA women in the study group scores better in the aspects of social 
function, physical function, role physical and role emotional than the non-pregnant reference 
women.  
HRQL declined during pregnancy in the RA and JIA women in the study group. However the 
RA women in the study group scored better in the HRQL aspects of mental health, vitality 
and role physical than the JIA women. The RA and JIA women in the study group had lower 
scores in the HRQL aspects of vitality, general health and physical function at 3rd trimester 
compared to baseline.  
Despite the wide range in scores, the women in the study group seemed to reach the same 
level in HRQL, DAS-28-CRP(3) and MHAQ as pre-pregnancy at the time of six months 
postpartum.  
 
Strengths and limitations  
Strengths of the present study are the use of prospectively collected data from two registers, 
frequently visits and high adherence. Unfortunately, the number of patients with pre-
pregnancy visit was limited. There is a challenge for the rheumatology units to get the patients 
to come in contact prior to pregnancy and many of the patients take contact with the 
rheumatology unit at the time their pregnancy is established (Figure 2). Pregnancy in women 
with chronic rheumatic diseases are considered risk pregnancy (47). Among women with 
chronic arthritis 50-60 % deliver children small for gestational age, and 30-50 % deliver 
before pregnancy week 37 (48). Not all women with RA and JIA are referred to the 
rheumatology units when pregnant, despite that related to pregnancy these women are 
supposed to be assessed once prior to pregnancy, and during pregnancy at the specialist care 
unit according to the National Service for Pregnancy and Rheumatic Disease (47). 
 
The number of rheumatic women giving birth each year in Norway is small. In the women 
with specified arthritis, including RA, JIA, psoriatic arthritis and ankylosing spondylitis 2736 
births were registered in the time period from 2000-2009 in the Norwegian Birth registry 
(Unpublished number given to this paper with content, 29th of October 2012 from Marianne 
Wallenius). Therefore, the number of participants available was quite restricted during a 
seven year perspective with recruiting patients to RevNatus. 
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The transition from childhood and adolescent into adult life involves challenges in coping 
strategies and adjustment processes for patients with JIA (49). It is  known that patients with 
JIA often have challenging transfers to adult rheumatology (50). One study have shown that 
29 % fail to meet to their first appointment at the adult rheumatology unit (50). Moreover,  
52 % failed to come in contact with the rheumatology unit within the first two years after 
transfer (50). Corresponding to the known dropout difficulties of JIA patients, five of the 
women with JIA in the study group with a six weeks visit failed to come to the visit six 
months postpartum (Figure 2).   
 
As a consequence of the inconsistent number of participants throughout the study period and 
several repeated measures, the linear mixed model analysis for incomplete dataset was 
regarded as a relevant method in order to study change in HRQL, disease activity and disease 
related function from pre-pregnancy, during pregnancy and postpartum. The distribution of 
the outcome variables was checked initially and we found no severe deviations from normal 
distribution. Therefore, using the generalized mixed effect model analysis for incomplete 
dataset was considered relevant, especially since there are no good alternative nonparametric 
tests. However, in order to inspect the results of change over time for the study group women, 
nonparametric analysis (Wilcoxon test for related samples) were used for the eight aspects of 
HRQL, disease activity and the disease related function. When using this nonparametric 
analysis, each disease specific study group were analysed separately (RA and JIA), thus 
inconsistent number of participants throughout the study period and consequently increasing 
risk of type II error (finding no significant differences even if there is one). However, the 
results from generalized mixed effect model were partly confirmed.  
 
One the other hand, there is a strength that we used more than one statistical approach in the 
present study and the statistical level of 0.05 seems adequate in the context of the clinical 
relevance for these women. Even so, a previous small study of HRQL in pregnant women 
with RA using only nonparametric analysis chose a lower significant level, due to multiple 
comparison (1). 
 
Due to the low number of participants the statistical power was restricted and all potential 
relevant variables influencing the HRQL could not be included in one integrated model. For 
example, it is known that age and work status may influence HRQL as well as disease activity 
(51). Futhermore, we could not study change in HRQL in the RA study group versus the JIA 
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study group throughout the pregnancy due to low number of data and restricted statistical 
power. 
 
Most of the patients with an active RA and JIA are in contact with the specialist care, 
however not all rheumatology units in Norway are linked to the RevNatus and NOR-DMARD 
register. Continuing collecting data is important to increase the number of women to the 
study; however, due to the low number of women with rheumatic disease giving birth each 
year enrolling women from other rheumatology units in Norway seems reasonably. In 
addition, multinational studies including countries that are comparable with Norway in 
rheumatology care enables larger number of patients, and thus more statistical power.    
 
Furthermore, the use of SF-36 to measure HRQL is a strength to the study. In rheumatology 
the SF-36 is most frequently used tools to measure health outcome (28, 32). There are no 
disease specific measurements for HRQL translated and validated into Norwegian. The SF-36 
has been validated on people living with RA after translation into Norwegian (40). However, 
the physical functioning measured with the SF-36 has shown not to cover all aspects of 
physical HRQL (39), therefore the MHAQ modified from HAQ (Health Assessment 
Questionnaire) (44) as a disease specific supplement to measure physical function was added 
in this study. The SF-36 was used in both the study group women and the non-pregnant 
reference women who made it possible to compare HRQL between the two groups. 
Furthermore, since SF-36 is a generic instrument frequently used in health care and in clinical 
trials to measure HRQL (28), enables us to compare these women to healthy controls in future 
studies.  
 
It is a strength that we used the DAS-28-CRP(3) for measuring disease activity which is 
regarded the most suitable version for use during pregnancy (22). However, the challenge 
with this instrument it is the inter-rater reliability in the joint count, since two different 
persons may score different in the same patient at the same time, depending on investigators 
technique in performing joint count (52). However, most of the patients included were 
measured by the same rheumatologist or nurse throughout the study period. This makes the 
measurements more reliable for change. 
 
A major limitation in the present study is the lack of a reference group of healthy women 
going through a pregnancy. Following a group of healthy women through pregnancy would 
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give valuable information on how rheumatic pregnant women differ from healthy pregnant 
women in HRQL before, during and after pregnancy. We had two groups of non-pregnant 
reference women (one with RA and one with JIA), but they were at baseline not quite 
comparable with the study group since the RA women in the study group used less DMARDs 
at baseline compared to the non-pregnant reference women and the JIA women in the study 
group scored better in DAS-28-CRP(3) and used less DMARDs at baseline compared to the 
JIA non-pregnant reference women.  
 
Another limitation in this study is the lack of information on gestational age and possible 
obstetric complications which may influence HRQL postpartum. All the women in the study 
group gave live births. Futhermore, marital status and parity of the non-pregnant women are 
unknown. 
 
Health related quality of life 
HRQL is influenced by the problems of daily life (32). Participating in life roles, such as 
motherhood, makes an important contribution on QOL, and illness in form of chronic 
inflammatory arthritis may influence participation in these roles (53).Pregnancy may 
influence the perception of HRQL, also in healthy women (54). 
  
It is expected that HRQL is experienced differently in women with chronic rheumatic diseases 
compared to healthy women, since the disease can have major impact on both physical and 
psychological health (1, 32). When comparing HRQL in the study group at baseline and six 
months postpartum to the non-pregnant reference women we found that especially the RA 
women in the study group scored better six months postpartum in the aspects of social 
function, physical function, role physical and role emotional. The JIA women in the study 
group scored better in the aspects of vitality and general health pre-pregnancy compared to 
the non-pregnant reference women. Another study of HRQL in healthy women confirms the 
positive effect of becoming a mother, with increased scores on physical function postpartum 
(1). In the present study, RA women in the study group had better HRQL than the JIA women 
in the study group in some aspects, i.e. the mental health, vitality and role physical aspects of 
SF-36 independent of time of study. A study of young adults with JIA found that the 
unpredictability of the disease development and possible reduced function affected their life 
(49). Another study has shown that pregnancy and raising children are important issue for 
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women with JIA (55). Women with JIA have had their chronic rheumatic disease longer than 
the RA women, therefore they may have experienced more impact on their life (14).   
 
Early pregnancy symptoms, such as nausea and fatigue are most common in the 1st trimester 
among pregnant women in general (54). Although these symptoms are expected to decline 
after the 12 first pregnancy weeks (56), other physical problems, such as pelvic pain, leg 
cramps, heartburn, constipation and weight gain often occur in the 2nd and 3rd trimester of 
pregnancy (54). One study has shown that healthy women have reported lower physical health 
in the 2nd and 3rd trimester (1). Another study on HRQL on healthy women showed declined 
scores on physical health and vitality aspects throughout the pregnancy (57). Women with RA 
and JIA experiences the same negative symptoms during pregnancy as the normal population 
(54), which is reflected in the present study i.e. the study group reported lower vitality and 
role physical in the study group for both RA and JIA women. The study group reported lower 
general health and physical function in the 3rd trimester. 
 
Function may be naturally influenced by pregnancy, and this is reflected in the results from 
the generalized mixed effect model of MHAQ which found higher scores (poorer) in 3rd 
trimester. Some of the activities included in the MHAQ, are more challenging as the 
pregnancy progress, also in healthy women, such as bending down to the floor to pick up 
clothes, and getting out of bed (Appendix 4).  
 
In 40-50 % of women RA and JIA, a postpartum flare is expected within three to six months 
after delivery (16, 22). This is a time when the newborn is small, and need a lot of care from 
their mother. Feeding, changing diapers, carrying the baby and getting up in the middle of the 
night to feed the baby is challenging with morning stiffness, swollen and tender joints and 
fatigue (6, 58, 59). In the study group, both women with RA and JIA reported lower scores 
(more pain) in the aspect of bodily pain six weeks postpartum. This is in accordance with one 
other study assessing RA patients 12 weeks postpartum (1).  
 
Planned pregnancies give the rheumatologist the opportunity to optimize the medical 
treatment before the pregnancy occurs, and also to help the women to reflect about their life 
situation before getting pregnant (47). The women are also able to think about the support 
they can receive from their network if a flare occurs postpartum. Having a partner have 
positive impact on HRQL (6). Patients with RA and JIA that comes in contact with their 
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rheumatologist in 1st and 2nd trimester, have less chance to get their medications adjusted, 
because there are medications that take up to 12 weeks to be effective (60). Since planning of 
pregnancy is the major success factor for women with chronic rheumatic diseases like RA and 
JIA (47), this is frequently addressed during rheumatology consultations for women in fertile 
age.  
Despite this we may assume that not all pregnancies included in the present study was 
planned with the rheumatology unit as shown by increasing number of women in the 
RevNatus registry during pregnancy (Figure 2).  
  
Disease activity during pregnancy 
In the present study, the study group of RA and JIA women differed from the non-pregnant 
reference women with RA and JIA in use of DMARDs. This may be explained by the fact 
that some DMARDs are not compatible with pregnancy and lactation (60). Patients with RA 
and JIA that come in contact with their rheumatologist in 1st and 2nd trimester, have less 
chance to get their medication adjusted, because there are medications that take up to 12 
weeks to be effective (60).  
The last larger studies on disease activity in patients with RA and JIA during and after 
pregnancy were published before it was known that it was safe to use some biological drugs 
up until pregnancy is established, and during lactation (16, 22, 47). This is a big advantage in 
treating these women the last 10 years. Today, women can start the biological treatment 
regimen 14 days after giving birth (47). In the present study this is reflected in the mean 
scores of DAS-28, which did not change from pre-pregnancy to six months postpartum (Table 
6).  
 
Practical implications 
This study have shown that the JIA women in the study group scored lower in the HRQL 
aspects than the RA women in the study group at baseline. This result supports what is 
already known about JIA patients and their difficult transfers to adult life and follow up their 
controls at the rheumatology unit. Our work in the transfer from child rheumatology unit to 
adult rheumatology units is an area we need to give more attention, to give these women the 
best possible opportunity to have control of disease, and to give the best possible tools to live 
with their disease in adulthood. This study also shows that going through a pregnancy not 
necessarily have a negative effect on HRQL, disease activity or disease related function, when 
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comparing pre-pregnancy scores to scores six months postpartum. The mean score for disease 
activity in the study group showed that they were in remission (low disease activity) pre-
pregnancy. This is a well-known success factor for pregnancies in women with chronic 
rheumatic diseases (47). This knowledge is confirmed in this study and we need to address 
this to these patients. Since we know that planning a pregnancy is a big issue for these 
women, this is valuable information for these women when deciding whether they should go 
through a pregnancy or not.   
 
Future recommendations for research 
In the future, a similar study on HRQL in RA and JIA patients should be done including a 
group of healthy women followed through a pregnancy. This would give us more information 
on how rheumatic women are differs from the normal population. Furthermore, information 
on the factors that may influence HRQL such as marital status, parity and pregnancy outcome 
should be included in future research. Extended follow-up time with visits 12 and 24 months 
postpartum will give more knowledge on the long-term effect of a pregnancy on HRQL.  
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Conclusion  
 
In the study group, the SF-36 scores for women with RA were better than the JIA patients in 
the HRQL aspects of mental health, vitality and role physical at baseline. Despite a wide 
range in scores, the women in the study group seemed to reach the same level in HRQL, 
DAS-28-CRP(3) and MHAQ as pre-pregnancy at the time of six months postpartum.  
HRQL is an important aspect of living with a chronic rheumatic disease, and planning a 
family is an important concern for these women. The women in the study group had a low 
mean score in DAS-28-CRP(3) pre-pregnancy reflecting that their disease was well controlled 
and in remission when the pregnancy occurred. This may be the reason the mean score of 
DAS-28-CRP(3) remained low six months postpartum. This knowledge is valuable when 
consulting these women. 
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Appendix 1 
 
Forespørsel om å bli registrert i en database for forskning på svangerskap og revmatiske 
sykdommer. 
 
Ved revmatologisk avdeling, St.Olavs Hospital er det et kompetansesenter innen svangerskap og 
revmatiske sykdommer. Formålet med kompetansesenteret er å gi råd og veiledning til pasienter 
og helsepersonell om problemstillinger knyttet til svangerskap og revmatiske sykdommer. 
Samtidig skal senteret drive forskning for å bedre kvaliteten på tilbudet til kvinner med en 
revmatisk sykdom som planlegger å bli gravid eller som er gravide. I forbindelse med denne 
studien samarbeider vi med Rikshospitalet/Radiumhospitalet om utarbeidelse av variabler og 
inkludering av pasienter. 
 
Ved å samle opplysninger om deg og din sykdom under svangerskapet i en database, vil vi kunne 
bruke disse dataene for å forske på ulike problemstillinger knyttet til svangerskap og revmatisk 
sykdom. Deltagelse vil medføre at du må fylle ut et spørreskjema om sykdomstilstanden din under 
svangerskapet og frem til ett år etter fødselen. Dette vil gjøres samtidig som du er til kontroll hos 
revmatolog. Det vil bli gjort opptil 7 registreringer i tiden før, under og fram til 1 år etter 
svangerskapet.  
 
Aktuelle data om svangerskapsutfall fra din pasientjournal vil bli overført til denne databasen. 
Databasen vil være permanent. Det vil ikke være personidentifiserbare data (personnummer, 
adresse, telefonnummer etc) i databasen. 
 
Vi spør deg herved om du kan tenke deg å delta i denne undersøkelsen, og dermed la dine 
medisinske data bli registrert i denne databasen. Ved å skrive din signatur på baksiden av dette 
arket (samtykkeerklæringen) gir du oss tillatelse til å registrere data fra spørreskjemaet og data om 
din sykdomsaktivitet og fødsel fra pasientjournalen. Dersom du på nytt blir gravid, vil du få en ny 
forespørsel om deltagelse. 
 
Det er helt frivillig å være registrert i databasen og du kan på hvilket som helst tidspunkt trekke 
deg fra videre deltagelse, eller kreve at opplysningene du har gitt blir slettet uten å måtte begrunne 
dette. Hvorvidt du velger å delta i dette prosjektet eller ikke, har ingen betydning for den 
behandling du vil få ved avdelingen. 
 
Alle opplysninger vil bli behandlet konfidensielt, og alle personer tilknyttet prosjektet har 
taushetsplikt. Dataene hentet ut fra databasen vil bli publisert som gruppedata, uten at den enkelte 
kan gjenkjennes.  
 
Prosjektet er meldt til Personvernombudet for forskning, Norsk samfunnsvitenskapelig 
datatjeneste AS og tilrådet av Regional komite for medisinsk forskningsetikk, Region Midt-
Norge. 
 
Ved behov for mer utfyllende informasjon kan du ta kontakt med oss.  
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Forskningssykepleier, Hege Svean Koksvik St. Olavs Hospital    tlf. 72 82 64 00  
Revmatolog, overlege Marianne Wallenius        tlf. 72 82 64 00 
 
 
 
 
 
 
 
 
Samtykkeerklæring: 
Jeg har mottatt informasjon og sier meg villig til å delta i prosjektet.  
 
 
 
 
 
 
 
 
 
 
 ………………………    ………………         ………….……………………………….. 
(sted)             (dato)          (signatur) 
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Appendix 3 
 
DAS-28 formula 
 
DAS28(4) = (0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR) + 0.014*GH 
 
DAS28(3) = [0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR)]*1.08 + 0.16 
 
DAS28-CRP(4) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 
0.96 
 
DAS28-CRP(3) = [0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1)] * 1.10 + 1.15 
 
High disease activity >5.1, low disease activity <3.2, remission <2.6 
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Appendix 4 
 
MHAQ – Modified Health Assesment Questionnaire 
 
 
 
 
 
 
 
